• Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=1676761).
  

PubMed=1676761; DOI=10.1093/jnci/83.13.938
Kim J.-H., Takahashi T., Chiba I., Park J.-G., Birrer M.J., Roh J.K., De Lee H., Kim J.-P., Minna J.D., Gazdar A.F.
Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines.
J. Natl. Cancer Inst. 83:938-943(1991)

PubMed=10402490; DOI=10.3892/ijmm.4.2.203
Rha S.Y., Noh S.H., Kim T.S., Yoo N.C., Roh J.K., Min J.S., Kim B.-S., Kim M.Y., Chung H.C.
Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancer.
Int. J. Mol. Med. 4:203-212(1999)

PubMed=18922971; DOI=10.1158/1541-7786.MCR-08-0166
Yu E.J., Lee Y., Rha S.Y., Kim T.S., Chung H.C., Oh B.K., Yang W.I., Noh S.H., Jeung H.-C.
Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
Mol. Cancer Res. 6:1554-1566(2008)

PubMed=18804159; DOI=10.1016/j.ygeno.2008.08.002
Jung J.-J., Jeung H.-C., Chung H.C., Lee J.O., Kim T.S., Kim Y.T., Noh S.H., Rha S.Y.
In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer.
Genomics 93:52-61(2009)

PubMed=25343454; DOI=10.1371/journal.pone.0111146; PMCID=PMC4208810
Choong M.-L., Tan S.-H., Tan T.-Z., Manesh S., Ngo A., Yong J.W.-Y., Yang H.H., Lee M.A.
Molecular integrative clustering of Asian gastric cell lines revealed two distinct chemosensitivity clusters.
PLoS ONE 9:E111146-E111146(2014)

PubMed=29435981; DOI=10.1002/ijc.31304
Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C., Kragh M., Horak I.D., Chung H.C., Rha S.Y.
Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.
Int. J. Cancer 143:151-159(2018)